Genmab A/S - Product Pipeline Review - 2012

Report Overview

Table of Contents

958.44

Select License Type

£958.44	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£1,916.88	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£2,875.33	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£958.44	Add to Wishlist
Change Currency	GBP EURO USD
	Order By Fax

Market	Healthcare and Medical
Report Type	Company Profile
Country	Global
Published	31 August 2012
Number of Pages	102
Report Delivery	Email
Delivery Lead Time	1-3 hours, 24 hour max
Publisher	Global Markets Direct
File Format	PDF

Genmab A/S - Product Pipeline Review - 2012 - This pharmaceuticals report, "Genmab A/S - Product Pipeline Review - 2012" provides data on the Genmab A/S's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from our proprietary databases, Genmab A/S's corporate website, SEC filings, investor presentations and featured press releases, both from Genmab A/S and industry-specific third party sources, put together by This team.

Scope

- Genmab A/S - Brief Genmab A/S overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Genmab A/S human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Genmab A/S with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Genmab A/S's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Genmab A/S's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Genmab A/S in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Genmab A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Genmab A/S.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Genmab A/S and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Genmab A/S; Genmab A/S - Key Therapeutics; Genmab A/S - Pipeline Overview and Promising Molecules; Genmab A/S - News; Genmab A/S - Latest Updates; Genmab A/S - Pipeline; Genmab A/S - Discontinued/Dormant Projects

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

£958.44	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£1,916.88	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£2,875.33	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£958.44	Add to Wishlist
Change Currency	GBP EURO USD

Table of Contents
List of Tables
List of Figures
Genmab A/S Snapshot
Genmab A/S Overview
Key Information
Key Facts
Genmab A/S - Research and Development Overview
Key Therapeutic Areas
Genmab A/S - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Genmab A/S - Pipeline Products Glance
Genmab A/S - Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Genmab A/S Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Genmab A/S - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Genmab A/S - Drug Profiles
Arzerra
Product Description
Mechanism of Action
R&D Progress
Arzerra + Bendamustine
Product Description
Mechanism of Action
R&D Progress
Arzerra + DHAP + Stem Cell Transplant
Product Description
Mechanism of Action
R&D Progress
Arzerra + Fludarabine + Cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
Daratumumab
Product Description
Mechanism of Action
R&D Progress
HuMax-CD32b
Product Description
Mechanism of Action
R&D Progress
HuMax-CD74-ADC
Product Description
Mechanism of Action
R&D Progress
HuMax-cMet
Product Description
Mechanism of Action
R&D Progress
HuMax-HepC
Product Description
Mechanism of Action
R&D Progress
HuMax-Her2
Product Description
Mechanism of Action
R&D Progress
HuMax-IL8
Product Description
Mechanism of Action
R&D Progress
HuMax-TAC
Product Description
Mechanism of Action
R&D Progress
HuMax-TF ADC
Product Description
Mechanism of Action
R&D Progress
Genmab A/S - Pipeline Analysis
Genmab A/S - Pipeline Products by Therapeutic Class
Genmab A/S - Pipeline Products by Route of Administration
Genmab A/S - Pipeline Products By Mechanism of Action
Genmab A/S - Recent Pipeline Updates
Genmab A/S - Dormant Projects
Genmab A/S - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Everolimus + R1507
R1507 + Avastin + Docetaxel
R1507 + Bevacizumab + mFOLFOX6
R1507 + Carboplatin + Etoposide
R1507 + Gemcitabine + Tarceva
R1507 + Irinotecan + Cetuximab
R1507 + Paclitaxel + Avastin
R1507 + Paclitaxel + Avastin + Carboplatin
R1507 + Pemetrexed
R1507 + Sorafenib
R1507 + Tarceva + Avastin
R1507 + Temozolomide
R1507 + Xeloda + Herceptin
RG1507
RG1507 + Letrozole
RG1507 + Tarceva
RG1671
Zalutumumab + Cisplatin + Docetaxel
Genmab A/S - Company Statement
Genmab A/S - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Genmab A/S, Recent Developments
Genmab A/S- Press Release
May 24, 2012: Genmab Receives DKK20m Milestone Payment From GSK
Apr 27, 2012: GlaxoSmithKline And Genmab Announce Submission Of New Drug Application For Arzerra In Japan
Mar 26, 2012: Genmab Announces Patent Settlement Agreement For Ofatumumab
Mar 19, 2012: Genmab Provides Update On Ofatumumab Phase III Head To Head Study In Diffuse Large B-cell Lymphoma
Dec 04, 2009: Genmab Announces RG1507 Update
Nov 10, 2009: Genmab Announces Start Of Ofatumumab Phase III Head To Head Study In DLBCL
Oct 26, 2009: GSK receives accelerated approval for Arzerra from FDA
Aug 26, 2009: Genmab Announces Positive Top-Line Results For Arzerra In Front Line NHL
Aug 17, 2009: GlaxoSmithKline And Genmab Announce Results From A Study Of Arzerra In Rituximab Refractory Follicular NHL
Aug 17, 2009: GlaxoSmithKline and Genmab announce results from a study of Arzerra in rituximab refractory follicular Non- Hodgkin's Lymphoma
Jul 29, 2009: GlaxoSmithKline And Genmab Announces Top-Line Results For Ofatumumab In Rheumatoid Arthritis
Jul 24, 2009: Genmab A/S Announces Recruitment Completed In Arzerra (ofatumumab) Phase II Study In Relapsed DLBCL
Jul 16, 2009: Genmab Announces Lift In Partial Clinical Hold For Zalutumumab
Jun 16, 2009: GSK announces US FDA extends the review of Arzerra (ofatumumab)
Jun 10, 2009: Genmab Completes Enrollment Of Patients For Pivotal Phase III Study Of Zalutumumab
Jun 03, 2009: Genmab Announces Partial Clinical Hold On Zalutumumab Studies
Feb 26, 2009: Genmab A/S Announces Arzerra (ofatumumab) MAA Accepted By EMEA
Feb 05, 2009: GlaxoSmithKline And Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) In Advanced Stage Blood Cancer
Jan 30, 2009: GlaxoSmithKline And Genmab Submits Arzerra (Ofatumumab) Application To FDA For The Treatment Of Advanced Stage Blood Cancer
Jan 05, 2009: Genmab Announces Interim Analysis Of Phase III Pivotal Study For Zalutumumab In Head And Neck Cancer
Financial Deals Landscape
Genmab A/S, Deals Summary
Genmab A/S, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Genmab Acquires Antibody Manufacturing Facility From PDL BioPharma
Genmab Acquires HuMax-Inflam Rights From Medarex
Partnerships
Genmab Enters Into Research Collaboration With Seattle Genetics
Genmab Enters Into Co-Development Agreement With H. Lundbeck
Genmab Enters Into Research Collaboration With Seattle Genetics
GlaxoSmithKline Amends Co-Development Agreement For Ofatumumab With Genmab
Genmab Enters Into Research Agreement With Pepscan Therapeutics
AlgoNomics Enters Into Research Agreement With Genmab
GlaxoSmithKline Enters Into Co-Development Agreement With Genmab
Licensing Agreements
ExonHit Therapeutics Enters Into Licensing Agreement With Genmab
Genmab Enters Into Licensing Agreement With Janssen Biotech For DuoBody Technology
Genmab Enters Into Licensing Agreement With Novartis For DuoBody Technology Platform
Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8
Genmab Announces Licensing Agreement For Daratumumab
TenX Biopharma Enters Into Licensing Agreement With Genmab
Genmab Enters Into Agreement With Cytokine
Genmab Enters Into License Agreement With Bionomics
Equity Offering
Genmab Completes Private Placement of $357 Million
Genmab Completes Private Placement Of $137 Million
Asset Transactions
Genmab Sells Arzerra Co-Promotion Rights To GlaxoSmithKline
Medarex Acquires Rights To Oncology Program From Genmab
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Genmab A/S, Key Information
Genmab A/S, Key Facts
Genmab A/S - Pipeline by Indication, 2012
Genmab A/S - Pipeline by Stage of Development, 2012
Genmab A/S - Monotherapy Products in Pipeline, 2012
Genmab A/S - Combination Treatment Modalities in Pipeline, 2012
Genmab A/S - Filed, 2012
Genmab A/S - Phase III, 2012
Genmab A/S - Phase II, 2012
Genmab A/S - Phase I, 2012
Genmab A/S - Pre-Clinical, 2012
Genmab A/S - Pipeline By Therapeutic Class, 2012
Genmab A/S - Pipeline By Route of Administration, 2012
Genmab A/S - Pipeline Products By Mechanism of Action, 2012
Genmab A/S - Recent Pipeline Updates, 2012
Genmab A/S - Dormant Developmental Projects,2012
Genmab A/S - Discontinued Pipeline Products, 2012
Genmab A/S, Subsidiaries
Genmab A/S, Deals Summary
Genmab Acquires Antibody Manufacturing Facility From PDL BioPharma
Genmab Acquires HuMax-Inflam Rights From Medarex
Genmab Enters Into Research Collaboration With Seattle Genetics
Genmab Enters Into Co-Development Agreement With H. Lundbeck
Genmab Enters Into Research Collaboration With Seattle Genetics
GlaxoSmithKline Amends Co-Development Agreement For Ofatumumab With Genmab
Genmab Enters Into Research Agreement With Pepscan Therapeutics
AlgoNomics Enters Into Research Agreement With Genmab
GlaxoSmithKline Enters Into Co-Development Agreement With Genmab
ExonHit Therapeutics Enters Into Licensing Agreement With Genmab
Genmab Enters Into Licensing Agreement With Janssen Biotech For DuoBody Technology
Genmab Enters Into Licensing Agreement With Novartis For DuoBody Technology Platform
Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8
Genmab Announces Licensing Agreement For Daratumumab
TenX Biopharma Enters Into Licensing Agreement With Genmab
Genmab Enters Into Agreement With Cytokine
Genmab Enters Into License Agreement With Bionomics
Genmab Completes Private Placement of $357 Million
Genmab Completes Private Placement Of $137 Million
Genmab Sells Arzerra Co-Promotion Rights To GlaxoSmithKline
Medarex Acquires Rights To Oncology Program From Genmab

List of Figures

Genmab A/S - Pipeline by Indication, 2012
Genmab A/S - Pipeline by Stage of Development, 2012
Genmab A/S - Monotherapy Products in Pipeline, 2012
Genmab A/S - Combination Treatment Modalities in Pipeline, 2012
Genmab A/S - Pipeline By Therapeutic Class, 2012
Genmab A/S - Pipeline By Route of Administration, 2012
Genmab A/S - Pipeline Products By Mechanism of Action, 2012 42

Visitor Comments

All Comments

Change Currency

GBP

EURO

USD

Last Viewed

Genmab A/S - Product Pipeline Review - 2012

Competitor Tracking

Do you need to track your competitors and customers on a continuous basis? We have the expertise to provide you with a cost-effective, fully customised competitor tracking portal, which collates data on your competitors on a continuous basis. Contact us for a free consultation and demonstration.

Become an Affiliate

Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?

Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website.

Custom Research

Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.

Healthcare and Medical	Type	Keywords Phrase All Words Any Word
Microsoft Windows users can hold the CTRL Key to select more than one sector or country at a time. Apple users can hold the CMD Key to do the same.	Country	Industry Sector
Publisher	Order By Relevance Date	Published In

Genmab A/S - Product Pipeline Review - 2012

Select License Type

Speak to an Advisor

Select License Type

Table of Contents

Visitor Comments

Change Currency

Last Viewed

Competitor Tracking

Become an Affiliate

Custom Research

News

Market Insights

Companies And Markets

Customer Support

Corporate Accounts

Contact Details

Contrast settings

Text size settings

All
Afghanistan
Africa
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua and Barbuda
Argentina
Armenia
Aruba
Asia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia-Herzegovina
Botswana
Bouvet Island
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Caribbean
Cayman Islands
Central African Republic
Central America
Central Europe
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Conch Republic
Cook Islands
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
Eastern Europe
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Europe
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Global
Greece
Greenland
Grenada
Guadeloupe (French)
Guam (USA)
Guatemala
Guernsey
Guinea
Guinea Bissau
Guyana
Haiti
Heard Island and McDonald Islans
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote D`Ivoire)
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kurdistan
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique (French)
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Middle East
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia (French)
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North America
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Island
Poland
Polynesia (French)
Portugal
Puerto Rico
Qatar
Republic of the Congo
Reunion
Romania
Russia
Rwanda
Saint Barthelemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Scandinavia
Schengen countries
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South America
South Georgia and the South Sandwich Islands
South Korea
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste (East Timor)
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Virgin Islands
Wallis and Futuna Islands
Western Sahara
Yemen
Zambia
Zimbabwe

All
Aerospace
Agriculture, Farming & Raw Materials
Automotive and Parts
Business Services
Chemicals
Construction
Consumer Goods
Defence
Energy and Utilities
Environmental
Finance and Banking
Food and Drink
Healthcare and Medical
Industrial
Information Technology
Leisure
Logistics
Media
Paper and Packaging
Publishing and Printing
Real Estate
Retail
Security
Telecommunications
Textiles and Clothing
Transportation
Travel